Study compares survival outcomes of different drugs for type 2 diabetes

Bottom Line: In a comparison of different classes of drugs used to lower blood sugar levels for patients with type 2 diabetes, sodium-glucose cotransporter 2 (SGLT-2) inhibitors or glucagon-like peptide 1(GLP-1) agonists were associated with a lower risk of death than dipeptidyl peptidase 4 (DPP-4) inhibitors or control (placebo or no treatment).

Why The Research Is Interesting: Several drug classes have emerged that are effective in improving blood sugar control for patients with type 2 diabetes, including SGLT-2 and DPP-4 inhibitors and GLP-1 agonists. The clinical effectiveness of these drugs compared to each other is not known.

Who and When: 176,310 study participants with type 2 diabetes in 236 randomized clinical trials in databases through October 2017

What (Study Measures): SGLT-2 inhibitors, GLP-1 agonists, DPP-4 inhibitors, and control (placebo, no treatment) (interventions); death from any cause (outcome).

How (Study Design): This was a network meta-analysis, which combines the results of multiple studies identified in a systematic review and quantitatively summarizes the overall association between interventions and outcomes measured across all studies.

Authors: Sean L. Zheng, B.M., B.Ch., M.A., M.R.C.P., Imperial College Healthcare NHS Foundation Trust, London, and coauthors

Study Limitations: Network meta-analysis respects randomization of clinical trials, but itself represents observational data, preventing conclusions on causality from being inferred.

Study Conclusions: In patients with type 2 diabetes, the use of SGLT-2 inhibitors or GLP-1 agonists was associated with better survival than DPP-4 inhibitors.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Global diabetes cases exceed 800 million highlighting urgent need for action